VERICEL CORP
VCELNASDAQTrading Snapshot
- Day Range
- $78.70 – $81.53
- 52-Week Range
- $28.95 – $49.32
- Volume
- $1.86B
- Avg Volume
- $2.30B
- Shares Outstanding
- 51.2M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $276M
- Last Q Revenue
- $77M
- P/E Ratio
- 83.8
- P/S Ratio
- 6.7x
- EPS (TTM)
- $0.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.3%
Why Investors Own VCEL
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VERICEL CORP
VCEL
StockOtter · stockotter.spaceAbout VERICEL CORP
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
VERICEL CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift VCEL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
VERICEL CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.